CFTR modulators tied to lower anxiety in children with CF

Children with cystic fibrosis (CF) using CFTR modulators showed lower anxiety levels than those not receiving the treatment, according to a study in Turkey published in the European Journal of Pediatrics. The research also found that parents of children on these therapies experienced lower rates of anxiety and depression.

How do CFTR modulators affect mental health?

Children not receiving CFTR modulators had significantly higher anxiety scores on the Screen for Child Anxiety-Related Emotional Disorders (SCARED) than those using the treatments. The researchers noted that these findings suggest a potential early psychosocial benefit for both patients and caregivers.

However, the study found no significant differences between the two groups regarding depression scores measured by the Children’s Depression Inventory (CDI). Similarly, there were no clear differences in quality of life as measured by the CF Questionnaire-Revised (CFQ-R).

What is the impact on parents and caregivers?

Parents of children who did not receive CFTR modulators scored significantly higher on the Beck Anxiety Inventory (BAI) and the Beck Depression Inventory (BDI). This indicates higher levels of both anxiety and depression compared to parents of children using the modulators.

While parents of children on modulators had somewhat higher quality-of-life scores on the World Health Organization Quality of Life-Short Form (WHOQOL-BREF), the researchers stated this difference was not statistically significant.

The study found that higher anxiety levels in children linked to higher anxiety and depression in their parents. Furthermore, better parental quality of life was associated with lower anxiety in both parents and children, as well as lower depression in parents.

How were the study results measured?

Researchers evaluated 53 children with a median age of 9 years and one parent for each child. Of the children, 24 received CFTR modulators for a median of 17 months, while 29 had never used the treatments.

Trikafta (elexacaftor/tezacaftor/ivacaftor) was the most common treatment, used by 87.5% of the modulator group. Other treatments included Kalydeco, Symdeko, and Orkambi. Among children not receiving modulators, 82.7% had genetic mutations that made them ineligible for available CFTR modulator therapies.

Did You Know? 82.7% of the children in the study who were not receiving CFTR modulators were ineligible for the treatments due to their specific genetic mutations.

Expert Insight: Samantha Carter notes that while these results are encouraging, the observational nature of the study means the modulators may not be the sole cause of improved mental health. The link between child anxiety and parental depression highlights the systemic emotional burden CF places on the entire family unit.

What may happen next?

Because this was a small, single-center observational study without before-and-after assessments, it cannot prove that CFTR modulators directly caused the mental health differences. Future research may be required to define these effects more clearly.

The researchers stated that their work contributes to the limited existing literature on the mental health and quality of life of pediatric CF patients and their parents. Additional studies could potentially explore if these psychosocial benefits persist over longer treatment durations.

Frequently Asked Questions

What are CFTR modulators? They are treatments designed to improve the function of the faulty CFTR protein, which normally controls the movement of salt and water in and out of cells, thereby easing physical symptoms of CF.
Did the modulators improve the quality of life for children? No, the study found no significant differences in quality of life between children receiving modulators and those who were not.
Which modulator was most frequently used in the study? Trikafta was used by 87.5% of the children receiving modulator therapy.

Do you believe mental health screenings should be a standard part of cystic fibrosis clinical care?